Risk factors for developing CMV gastroenteritis in the multivariate analysis
| . | Hazard ratio (95% CI) . | P value . |
|---|---|---|
| Age, category | ||
| <50 | 1 | Reference |
| ≥50 | 1.60 (1.16-2.22) | .004 |
| Sex match between recipient and donor | ||
| Female recipient or male to male | 1 | Reference |
| Female to male | 0.98 (0.69-1.39) | .913 |
| Recipient/donor CMV serostatus | ||
| Negative/positive | 1 | Reference |
| Positive/negative | 1.80 (0.91-3.56) | .091 |
| Positive/positive | 1.85 (0.97-3.56) | .064 |
| Letermovir prophylaxis | ||
| No | 1 | Reference |
| Yes | 0.50 (0.25-0.99) | .047 |
| Disease | ||
| AML | 1 | Reference |
| ALL | 1.15 (0.78-1.71) | .474 |
| MDS | 1.35 (0.90-2.03) | .144 |
| CML | 1.40 (0.66-2.97) | .385 |
| ATL | 1.20 (0.58-2.48) | .620 |
| NHL | 1.20 (0.63-2.30) | .585 |
| MPN | 1.15 (0.52-2.53) | .733 |
| DRI | ||
| Low | 1 | Reference |
| Intermediate | 1.47 (0.73-2.94) | .277 |
| High | 1.65 (0.74-3.68) | .217 |
| KPS | ||
| >80% | 1 | Reference |
| ≤80% | 0.75 (0.49-1.16) | .195 |
| HCT-CI | ||
| <2 | 1 | Reference |
| ≥2 | 0.93 (0.67-1.28) | .646 |
| Donor source | ||
| HLA matched related | 1 | Reference |
| HLA 1-antigen-mismatched related | 1.20 (0.53-2.71) | .660 |
| HLA matched unrelated | 0.84 (0.54-1.31) | .449 |
| HLA 1-locus-mismatched unrelated | 1.36 (0.91-2.03) | .130 |
| Umbilical cord blood | 0.85 (0.45-1.58) | .597 |
| Haploidentical | 0.72 (0.34-1.52) | .390 |
| Conditioning intensity | ||
| Myeloablative | 1 | Reference |
| Reduced intensity | 1.10 (0.80-1.50) | .559 |
| GVHD prophylaxis | ||
| MTX and CNI | 1 | Reference |
| MMF and CNI | 1.73 (1.08-2.77) | .024 |
| Other | 1.59 (0.86-2.93) | .139 |
| In vivo T-cell depletion | ||
| No | 1 | Reference |
| Yes | 1.11 (0.68-1.80) | .684 |
| Year of HCT | ||
| 2008-2013 | 1 | Reference |
| 2014-2019 | 1.00 (0.75-1.34) | .986 |
| Organ involvement at the development of grade II-IV acute GVHD | ||
| Skin GVHD | ||
| No | 1 | Reference |
| Yes | 1.26 (0.90-1.76) | .187 |
| Lower-gut GVHD | ||
| No | 1 | Reference |
| Yes | 2.17 (1.58-2.98) | <.001 |
| Liver GVHD | ||
| No | 1 | Reference |
| Yes | 1.32 (0.78-2.26) | .304 |
| Use of systemic steroids | ||
| No | 1 | Reference |
| Yes | 1.78 (1.16-2.74) | .008 |
| . | Hazard ratio (95% CI) . | P value . |
|---|---|---|
| Age, category | ||
| <50 | 1 | Reference |
| ≥50 | 1.60 (1.16-2.22) | .004 |
| Sex match between recipient and donor | ||
| Female recipient or male to male | 1 | Reference |
| Female to male | 0.98 (0.69-1.39) | .913 |
| Recipient/donor CMV serostatus | ||
| Negative/positive | 1 | Reference |
| Positive/negative | 1.80 (0.91-3.56) | .091 |
| Positive/positive | 1.85 (0.97-3.56) | .064 |
| Letermovir prophylaxis | ||
| No | 1 | Reference |
| Yes | 0.50 (0.25-0.99) | .047 |
| Disease | ||
| AML | 1 | Reference |
| ALL | 1.15 (0.78-1.71) | .474 |
| MDS | 1.35 (0.90-2.03) | .144 |
| CML | 1.40 (0.66-2.97) | .385 |
| ATL | 1.20 (0.58-2.48) | .620 |
| NHL | 1.20 (0.63-2.30) | .585 |
| MPN | 1.15 (0.52-2.53) | .733 |
| DRI | ||
| Low | 1 | Reference |
| Intermediate | 1.47 (0.73-2.94) | .277 |
| High | 1.65 (0.74-3.68) | .217 |
| KPS | ||
| >80% | 1 | Reference |
| ≤80% | 0.75 (0.49-1.16) | .195 |
| HCT-CI | ||
| <2 | 1 | Reference |
| ≥2 | 0.93 (0.67-1.28) | .646 |
| Donor source | ||
| HLA matched related | 1 | Reference |
| HLA 1-antigen-mismatched related | 1.20 (0.53-2.71) | .660 |
| HLA matched unrelated | 0.84 (0.54-1.31) | .449 |
| HLA 1-locus-mismatched unrelated | 1.36 (0.91-2.03) | .130 |
| Umbilical cord blood | 0.85 (0.45-1.58) | .597 |
| Haploidentical | 0.72 (0.34-1.52) | .390 |
| Conditioning intensity | ||
| Myeloablative | 1 | Reference |
| Reduced intensity | 1.10 (0.80-1.50) | .559 |
| GVHD prophylaxis | ||
| MTX and CNI | 1 | Reference |
| MMF and CNI | 1.73 (1.08-2.77) | .024 |
| Other | 1.59 (0.86-2.93) | .139 |
| In vivo T-cell depletion | ||
| No | 1 | Reference |
| Yes | 1.11 (0.68-1.80) | .684 |
| Year of HCT | ||
| 2008-2013 | 1 | Reference |
| 2014-2019 | 1.00 (0.75-1.34) | .986 |
| Organ involvement at the development of grade II-IV acute GVHD | ||
| Skin GVHD | ||
| No | 1 | Reference |
| Yes | 1.26 (0.90-1.76) | .187 |
| Lower-gut GVHD | ||
| No | 1 | Reference |
| Yes | 2.17 (1.58-2.98) | <.001 |
| Liver GVHD | ||
| No | 1 | Reference |
| Yes | 1.32 (0.78-2.26) | .304 |
| Use of systemic steroids | ||
| No | 1 | Reference |
| Yes | 1.78 (1.16-2.74) | .008 |
Bold indicates statistical significance.